Remarkably, the BLI measurement of CSP-FL–specific (Fig. 6A, 6B) and NANP6-specific (Fig. 6C, 6D) binding responses (open circles) of both groups of vaccinees previously observed to have high-, medium-, and low-Ab titers against these Ags in an ELISA assay exhibited a similar trend in agreement, exemplifying the suitability of this BLI assay for evaluating serum Ab responses to CSP-containing malaria vaccine candidates. The gene discussed is DNAJC5; the disease is malaria.